• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Possibility of pharmacogenetic approach suicide prevention in pediatoric major depressive disorder treatment.

Research Project

Project/Area Number 20790732
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeSingle-year Grants
Research Field Pediatrics
Research InstitutionKumamoto University

Principal Investigator

KAWATANI Junko  Kumamoto University, 医学部附属病院, 医員 (30423669)

Project Period (FY) 2008 – 2010
Project Status Completed (Fiscal Year 2010)
Budget Amount *help
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2010: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Keywords小児社会医学 / 小児 / うつ病 / 遺伝子多型 / SSRI / 遺伝子
Research Abstract

Screenings were conducted on 127 patients, and 43 patients (16boys and 27 girls ; mean age, 14.3 years ; standard deviation [SD], 1.3years) who have shown predisposition for depression were selected based on a Zung self-rating depression scale (SDS) of 40 points or above and Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR). The diagnosis of Depressive disorder was established by two raters including Licensed pediatric-psychological clinician using the Structured Clinical Interview. One hundred healthy subjects (23-68 years) were used as control in the study. Both groups were genotyped for 5-HTTLPR and BDNF. The frequency of the 5-HTTLPR variant was described as below : S allele (sl and ss genotype) was 98% , and for BDNF Val66Met was 67% in the control group. The frequency of the 5-HTTLPR variant was described as below : S allele (sl and ss genotype) was 94% , and for BDNF Val66Met was 70% in the patient group. No significant difference for the frequency of the 5-HTTLPR(χ^2test,p=0.20) and BDNF variants (χ^2test,p=0.76)was found between the control group and the patient group. The patients were randomly assigned to either paroxetine20mg/day or fuluvoxamin25mg/day for 6weeks. All patients were evaluated initially and at weeks 6 using Zung self-rating depression scale (SDS). Patients who showed a minimum of 10% decrease in the SDS score after 6 weeks of treatment were defined as a responder. The frequencies of the 5-HTTLPR genotypes did not significantly differ between the responder and in the non-responder group(χ^2test, p=0.33). The frequencies of the BDNF genotypes did not significantly differ between the responders and in the non-responders(χ^2test,p=0.8). Since the sample size is small, further sample collection is needed. Moreover, considering 5-HTTLPE is multi-allelic, the SSRI used are divided into paroxetine and fuluvoxamin, and gender is not considered in this study, further analysis is needed.

Report

(4 results)
  • 2010 Annual Research Report   Final Research Report ( PDF )
  • 2009 Annual Research Report
  • 2008 Annual Research Report

URL: 

Published: 2008-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi